Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/13/2025

Dexamethasone to Prednisone Conversion Guidelines

Standard Conversion Ratio

  • The standard conversion ratio from dexamethasone to prednisone is approximately 1:2.5, meaning 8 mg of dexamethasone is equivalent to 20 mg of prednisone, as supported by the United States Cutaneous Lymphoma Consortium guidelines 1, 2, 3
  • The American Academy of Dermatology recommends using a conversion ratio of 1:2.5 when switching from dexamethasone to prednisone for general anti-inflammatory purposes 1, 2, 3

Clinical Application Examples

  • When switching from prednisone 5 mg twice daily to dexamethasone, the National Comprehensive Cancer Network recommends using approximately 4 mg dexamethasone once daily 4, 5
  • For abiraterone therapy in prostate cancer, the National Comprehensive Cancer Network recommends switching from prednisone 10 mg daily to dexamethasone 0.5-1 mg daily, representing a lower conversion ratio to minimize mineralocorticoid effects 4, 5

Important Pharmacokinetic Considerations

  • Dexamethasone has minimal mineralocorticoid activity compared to prednisone, making direct milligram-to-milligram conversions potentially misleading in conditions where mineralocorticoid effects matter, as noted by the National Comprehensive Cancer Network 4, 5

Practical Conversion Guidelines

  • For general anti-inflammatory purposes, the American Academy of Dermatology suggests using 1 mg dexamethasone for every 2.5 mg prednisone 1, 2, 3
  • For immune thrombocytopenia, the American Society of Hematology suggests that dexamethasone 40 mg daily × 4 days can be used as an alternative to prednisone 0.5-2 mg/kg/day, though prednisone is preferred in children due to better tolerability 6, 7

Critical Caveats

  • The conversion ratio varies by clinical context and should not be applied universally across all conditions, as emphasized by the National Comprehensive Cancer Network 4, 5